Cardiovascular Diabetology

SEPTEMBER 15, 2024

Background Heart failure (HF) is a serious and common condition affecting millions of people worldwide, with obesity being a major cause of metabolic disorders such as diabetes and cardiovascular disease. During the 4.22-year

Obesity 98

Obesity Heart Failure Diabetes Cardiomyopathy 98

Science Daily - Heart Disease

NOVEMBER 20, 2024

Weight-loss and diabetes drug tirzepatide can reduce the risk of death or worsening heart failure for patients with obesity and heart failure with preserved pump function, new research reveals.

Heart Failure 112

Heart Failure Obesity Diabetes Research 112

Science Daily - Heart Disease

AUGUST 21, 2024

An analysis based on a proposed heart failure risk prediction tool reveals that the incidence of heart failure may be 2- to 3-fold higher among American Indian adults compared to people in other population groups.

Heart Failure 106

Heart Failure Risk Factors Blood Pressure Heart Attack 106

DAIC

MARCH 25, 2025

Ten presentations will feature new data from the pivotal Phase III FINEARTS-HF cardiovascular (CV) outcomes trial, which investigated KERENDIA for treatingt adult patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of 40%, i.e., mildly reduced LVEF (HFmrEF) or preserved LVEF (HFpEF). Additional ACC.25

Preserved Ejection Fraction 52

Preserved Ejection Fraction Heart Failure Kidney Disease Research 52

Heart BMJ

MARCH 26, 2025

Heart failure (HF) is one of the significant complications in patients with myocardial infarction (MI), leading to increased risk for cardiovascular morbidity and mortality. Common predictors include older age, prior hypertension, diabetes and atrial fibrillation. HFrEF is more commonly.

Myocardial Infarction 52

Myocardial Infarction Preserved Ejection Fraction Heart Failure Aortic valve 52

Science Daily - Heart Disease

MARCH 5, 2025

Research shows that a common type of diabetes medication could help cancer patients make a better long-term recovery. Many cancer patients go on to develop heart failure -- because of the cancer itself and also due to chemotherapy.

Cancer 99

Cancer Diabetes Heart Failure Research 99

Medical Xpress - Cardiology

NOVEMBER 21, 2024

A drug used to help patients lose weight and manage diabetes may also help those with heart failure, an international clinical trial shows.

Heart Failure 98

Heart Failure Diabetes 98

Cardiovascular Diabetology

NOVEMBER 19, 2024

Diabetic heart disease may eventually lead to heart failure, a leading cause of mortality in diabetic individuals. The lack of effective treatments for diabetes-induced heart failure may result from a failure.

Diabetes 105

Diabetes Heart Failure Heart Disease Research 105

Medical Xpress - Cardiology

JANUARY 2, 2024

A two-step screening protocol that combines clinical risk assessment with biomarker testing can more effectively identify which patients with type 2 diabetes need medication to prevent heart failure, according to a study led by UT Southwestern Medical Center researchers.

Heart Failure 80

Heart Failure Diabetes Biomarkers Research 80

DAIC

JUNE 21, 2024

announced that the peer-reviewed Journal of the American College of Cardiology: Heart Failure has published a research paper concluding that INPEFA (sotagliflozin) is cost-effective for people with diabetes and recent worsening heart failure using commonly accepted willingness-to-pay thresholds. “Our

Heart Failure 105

Heart Failure Preserved Ejection Fraction Diabetes Research 105

DAIC

APRIL 30, 2024

Getty Images milla1cf Tue, 04/30/2024 - 12:56 April 30, 2024 — A multicenter study led by Vanderbilt University Medical Center ( VUMC ) and Lipscomb University College of Pharmacy in Nashville has identified a potential new treatment for acute heart failure , a leading cause of hospitalization and death. hospitals from emergency rooms.

Heart Failure 105

Heart Failure Hospital Research COVID-19 105

Med Page Today

APRIL 7, 2024

(MedPage Today) -- ATLANTA -- Weight loss and heart failure benefits with semaglutide (Wegovy) extended to patients with obesity-related heart failure with preserved ejection fraction (HFpEF) who have type 2 diabetes, the STEP-HFpEF DM trial showed.

Preserved Ejection Fraction 96

Preserved Ejection Fraction Diabetes Heart Failure Obesity 96

Med Page Today

JANUARY 11, 2025

(MedPage Today) -- TTHealthWatch is a weekly podcast from Texas Tech. In it, Elizabeth Tracey, director of electronic media for Johns Hopkins Medicine in Baltimore, and Rick Lange, MD, president of the Texas Tech University Health Sciences Center.

Heart Failure 98

Heart Failure Exercise Diabetes 98

Cardiovascular Diabetology

MARCH 21, 2025

Mineralocorticoid receptor antagonists (MRAs) are often underutilized in patients with heart failure (HF), particularly those with diabetes and/or chronic kidney disease (CKD). However, the impact of concurren.

Kidney Disease 59

Kidney Disease Heart Failure Diabetes Hospital 59

Science Daily - Heart Disease

JULY 24, 2024

In mice with heart failure with preserved ejection fraction (HFpEF), increasing ketone supply to the heart allowed their hearts to utilize more ketones and produce more energy.

Preserved Ejection Fraction 115

Preserved Ejection Fraction Diabetes Heart Failure 115

American College of Cardiology

APRIL 6, 2024

The goal of the STEP-HFpEF DM trial was to compare the safety and efficacy of semaglutide among patients with obesity-related heart failure with preserved ejection fraction (HFpEF) and type 2 diabetes mellitus (DM).

Preserved Ejection Fraction 63

Preserved Ejection Fraction Heart Failure Obesity Diabetes 63

Cardiovascular Diabetology

AUGUST 6, 2024

Objective To explore trends in prognosis and use of glucose-lowering drugs (GLD) in patients with diabetes and coronary artery disease (CAD). Research design and methods All patients with diabetes and CAD undergoing a coronary angiography between 2010 and 2021 according to the Swedish Angiography and Angioplasty Registry were included.

Coronary Artery Disease 98

Coronary Artery Disease Diabetes Myocardial Infarction Heart Failure 98

HCPLive

JUNE 18, 2024

New research from the SOLOST-WHF trial suggests sotagliflozin is a cost-effective treatment for diabetes patients with recent heart failure, with high cost-effectiveness probability.

Heart Failure 69

Heart Failure Diabetes Research 69

DAIC

APRIL 9, 2024

Decline in exercise ability is a hallmark of progression to overt heart failure. The international ARISE-HF trial was designed to test the effectiveness of the investigational drug AT-001 at stabilizing exercise capacity in patients with diabetic cardiomyopathy. Patients had had Type 2 diabetes for an average of 14 years.

Heart Failure 52

Heart Failure Diabetes Cardiomyopathy Exercise 52

Cardiovascular Diabetology

JANUARY 8, 2024

Myocardial infarction (MI), stroke, peripheral arterial disease (PAD), heart failure (HF) and chronic kidney disease (CKD) are common cardiovascular renal diseases (CVRD) manifestations for type 2 diabetes.

Peripheral Arterial Disease 105

Peripheral Arterial Disease Myocardial Infarction Kidney Disease Diabetes 105

Medical Xpress - Cardiology

JANUARY 20, 2025

People with type 2 diabetes had significantly fewer heart attacks, strokes, heart failures, and deaths from cardiovascular disease when their blood pressure was lower than the current standard goal, a UT Southwestern Medical Center researcher and his colleagues found.

Blood Pressure 86

Blood Pressure Cardiovascular Disease Diabetes Heart Attack 86

HCPLive

MARCH 31, 2025

Justin Mark, MD, discusses an analysis of the FIGHT trial looking at racial and ethnic differences in heart failure outcomes.

Heart Failure 59

Heart Failure Outcomes Diabetes 59

Medical Xpress - Cardiology

DECEMBER 30, 2023

For patients with heart failure and type 2 diabetes (T2D), dapagliflozin does not reduce urinary albumin-to-creatinine ratio (UACR) but does reduce some cardiovascular events, according to a study published online Nov. 27 in eClinicalMedicine.

Heart Failure 75

Heart Failure Diabetes 75

Cardiovascular Diabetology

JANUARY 19, 2024

Diabetes mellitus (DM) is associated with a worse prognosis in patients with heart failure. Our aim was to analyze the clinical and imaging features of patients with DM and their association with outcomes in c.

Diabetes 95

Diabetes Outcomes Heart Failure Cardiomyopathy 95

Cardiovascular Diabetology

JUNE 14, 2024

Diabetic kidney disease is an established risk factor for heart failure. However, the impact of incident heart failure on the subsequent risk of renal failure has not been systematically assessed in diabetic p.

Kidney Disease 52

Kidney Disease Heart Failure Diabetes Risk Factors 52

Cardiovascular Diabetology

MARCH 20, 2025

The triglyceride-glucose index serves as a dependable biomarker for gauging insulin resistance linked to cardiovascular disease. Our study was designed to investigate how the trajectory of the triglyceride-glu.

Heart Failure 86

Heart Failure Biomarkers Cardiovascular Disease Diabetes 86

Science Daily - Heart Disease

FEBRUARY 14, 2025

New research shows sotagliflozin is the only drug in its class to demonstrate these results.

Heart attacks 112

Heart attacks Heart Attack Kidney Disease Heart Failure 112

Cardiovascular Diabetology

AUGUST 30, 2024

Heart failure with preserved ejection fraction (HFpEF) is common in type 2 diabetes mellitus (T2D), leading to high morbidity and mortality. Managing HFpEF in diabetic patients is challenging with limited trea.

Preserved Ejection Fraction 59

Preserved Ejection Fraction Heart Failure Diabetes Research 59

European Journal of Heart Failure

NOVEMBER 26, 2024

Discontinuation and reinitiation of mineralocorticoid receptor antagonists (MRA) in patients with heart failure and reduced ejection fraction (HFrEF). BMI, body mass index; eGFR, estimated glomerular filtration rate; NYHA, New York Heart Association. 1.34), ischaemic heart disease (HR 1.20, 95% CI 1.09–1.31),

Heart Failure 71

Heart Failure Kidney Disease Atrial Fibrillation BMI 71

CardiacWire

OCTOBER 6, 2024

Finerenone is already approved to reduce cardiovascular and kidney disease risks in patients with type 2 diabetes-associated CKD, but not for HF. The post Finerenone’s Early Heart Failure Impact appeared first on Cardiac Wire. And with a new drug, knowing which patients to target is a good way to start.

Heart Failure 59

Heart Failure Blood Pressure Kidney Disease Diabetes 59

Cardiovascular Diabetology

JUNE 6, 2024

Sodium glucose cotransporter 2 (SGLT2) inhibitors significantly improve cardiovascular outcomes in diabetic patients; however, the mechanism is unclear. We hypothesized that dapagliflozin improves cardiac outc.

Diabetes 64

Diabetes Heart Failure Outcomes Research 64

Cardiovascular Diabetology

APRIL 28, 2024

Glycemic control, as measured by glycosylated hemoglobin (HbA1c), is an important biomarker to evaluate diabetes severity and is believed to be associated with heart failure development. Type 2 diabetes mellit.

Heart Failure 52

Heart Failure Diabetes Biomarkers Outcomes 52

European Journal of Heart Failure

OCTOBER 9, 2024

Cardiovascular outcomes with exenatide in type 2 diabetes (T2D) according to left ventricular ejection fraction (LVEF): the EXSCEL trial. CI, confidence interval; CVD, cardiovascular disease; GLP-1 RA, glucagon-like peptide-1 receptor agonist; HHF, hospitalization for heart failure; HR, hazard ratio; NYHA, New York Heart Association.

Diabetes 75

Diabetes Outcomes Heart Failure Obesity 75

Journal of the American Heart Association

FEBRUARY 19, 2025

Journal of the American Heart Association, Ahead of Print. BackgroundLimited studies show an association between elevated total homocysteine (tHcy) and heart failure (HF) risk, but no studies have assessed whether this association differs by HF subtype.

Atherosclerosis 75

Atherosclerosis Heart Failure Preserved Ejection Fraction Diabetes 75

DAIC

MARCH 25, 2025

Ten presentations will feature new data from the pivotal Phase III FINEARTS-HF cardiovascular (CV) outcomes trial, which investigated KERENDIA for treatingt adult patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of 40%, i.e., mildly reduced LVEF (HFmrEF) or preserved LVEF (HFpEF). Additional ACC.25

Preserved Ejection Fraction 52

Preserved Ejection Fraction Heart Failure Research Academic 52

Cardiovascular Diabetology

AUGUST 11, 2024

We evaluated the prevalence of “heart stress” (HS) based on NT-proBNP cut-points proposed by the 2023 Consensus of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) in asymptomati.

Blood Pressure 111

Blood Pressure Heart Failure Hypertension Diabetes 111

Cardiovascular Diabetology

MARCH 4, 2025

Although previous studies have evaluated renal function decline in patients with heart failure (HF), there is limited evidence on long-term renal trajectories, especially in patients with concomitant HF and ty.

Heart Failure 59

Heart Failure Diabetes Research 59